Early Loss of Fat Mass During Chemoradiotherapy Predicts Overall Survival in Locally Advanced Squamous Cell Carcinoma of the Lung, but Not in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

A. C. H. Willemsen; J. H. R. J. Degens; L. W. J. Baijens; A-M C. Dingemans; A. Hoeben; F. J. P. Hoebers; D. K. M. De Ruysscher; A. M. W. J. Schols

doi:10.3389/fnut.2020.600612

Early Loss of Fat Mass During Chemoradiotherapy Predicts Overall Survival in Locally Advanced Squamous Cell Carcinoma of the Lung, but Not in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

A. C. H. Willemsen^*, J. H. R. J. Degens, L. W. J. Baijens, A-M C. Dingemans, A. Hoeben, F. J. P. Hoebers, D. K. M. De Ruysscher, A. M. W. J. Schols

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: Cancer cachexia is highly prevalent in advanced non-small cell lung cancer (NSCLC) and locally advanced head and neck squamous cell carcinoma (LAHNSCC), and compromises treatment tolerance and overall survival (OS). NSCLC and LAHNSCC patients share similar risk factors, and receive comparable anti-cancer treatment regimens. The aim of this study was to determine the predictive value of body composition assessed by bioelectrical impedance analysis (BIA) and handgrip strength (HGS) (baseline and early changes during therapy) on OS in NSCLC and LAHNSCC patients treated with platinum-based chemoradiotherapy (CRT) or cetuximab-based bioradiotherapy (BRT). To elucidate potential underlying determinants of early changes in body composition and HGS, specific (fat and fat free) mass loss patterns of squamous NSCLC (sNSCLC) were compared to human papilloma virus negative (HPV-) LAHNSCC patients treated with CRT.

Methods: Between 2013 and 2016, BIA and HGS were performed at baseline and after 3 weeks of CRT/BRT in LAHNSCC and NSCLC patients treated with curative intent.

Results: Two hundred thirty-three patients were included for baseline measurements. Fat free mass index (FFMI) and HGS2%) in the first 3 weeks of CRT (sNSCLC n = 24, HPV- LAHNSCC n = 23), the FM change was -1.4 +/- 14.5% and -8.7 +/- 9.0% in sNSCLC and HPV- LAHNSCC patients, respectively (p <0.05). Fat fee mass change was -5.6 +/- 6.3% and -4.0 +/- 4.3% for sNSCLC and HPV- LAHNSCC, respectively (p = 0.31).

Conclusion: FFMI and HGS

Original language	English
Article number	600612
Number of pages	11
Journal	Frontiers in nutrition
Volume	7
DOIs	https://doi.org/10.3389/fnut.2020.600612
Publication status	Published - 26 Nov 2020

Keywords

hand grip strength (HGS)
locally advanced (stage III) non-small cell lung cancer
locally advanced head and neck cancer
bioelectrical impedance analysis
cachexia
weight loss
chemoradiotherapy (CRT)
OBSTRUCTIVE PULMONARY-DISEASE
CONCURRENT CHEMORADIOTHERAPY
PROGNOSTIC VALUE
CANCER PATIENTS
WEIGHT-LOSS
CHEMOTHERAPY
RADIOTHERAPY
MUSCLE
OUTCOMES
INFLAMMATION

Access to Document

10.3389/fnut.2020.600612Licence: CC BY

Cite this

Willemsen, A. C. H., Degens, J. H. R. J., Baijens, L. W. J., Dingemans, A.-M. C., Hoeben, A., Hoebers, F. J. P., De Ruysscher, D. K. M., & Schols, A. M. W. J. (2020). Early Loss of Fat Mass During Chemoradiotherapy Predicts Overall Survival in Locally Advanced Squamous Cell Carcinoma of the Lung, but Not in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Frontiers in nutrition, 7, Article 600612. https://doi.org/10.3389/fnut.2020.600612

@article{6580f2ece8554e5fb7f2e573863b2d97,

title = "Early Loss of Fat Mass During Chemoradiotherapy Predicts Overall Survival in Locally Advanced Squamous Cell Carcinoma of the Lung, but Not in Locally Advanced Squamous Cell Carcinoma of the Head and Neck",

abstract = "Background: Cancer cachexia is highly prevalent in advanced non-small cell lung cancer (NSCLC) and locally advanced head and neck squamous cell carcinoma (LAHNSCC), and compromises treatment tolerance and overall survival (OS). NSCLC and LAHNSCC patients share similar risk factors, and receive comparable anti-cancer treatment regimens. The aim of this study was to determine the predictive value of body composition assessed by bioelectrical impedance analysis (BIA) and handgrip strength (HGS) (baseline and early changes during therapy) on OS in NSCLC and LAHNSCC patients treated with platinum-based chemoradiotherapy (CRT) or cetuximab-based bioradiotherapy (BRT). To elucidate potential underlying determinants of early changes in body composition and HGS, specific (fat and fat free) mass loss patterns of squamous NSCLC (sNSCLC) were compared to human papilloma virus negative (HPV-) LAHNSCC patients treated with CRT.Methods: Between 2013 and 2016, BIA and HGS were performed at baseline and after 3 weeks of CRT/BRT in LAHNSCC and NSCLC patients treated with curative intent.Results: Two hundred thirty-three patients were included for baseline measurements. Fat free mass index (FFMI) and HGS2%) in the first 3 weeks of CRT (sNSCLC n = 24, HPV- LAHNSCC n = 23), the FM change was -1.4 +/- 14.5% and -8.7 +/- 9.0% in sNSCLC and HPV- LAHNSCC patients, respectively (p <0.05). Fat fee mass change was -5.6 +/- 6.3% and -4.0 +/- 4.3% for sNSCLC and HPV- LAHNSCC, respectively (p = 0.31).Conclusion: FFMI and HGS",

keywords = "hand grip strength (HGS), locally advanced (stage III) non-small cell lung cancer, locally advanced head and neck cancer, bioelectrical impedance analysis, cachexia, weight loss, chemoradiotherapy (CRT), OBSTRUCTIVE PULMONARY-DISEASE, CONCURRENT CHEMORADIOTHERAPY, PROGNOSTIC VALUE, CANCER PATIENTS, WEIGHT-LOSS, CHEMOTHERAPY, RADIOTHERAPY, MUSCLE, OUTCOMES, INFLAMMATION",

author = "Willemsen, {A. C. H.} and Degens, {J. H. R. J.} and Baijens, {L. W. J.} and Dingemans, {A-M C.} and A. Hoeben and Hoebers, {F. J. P.} and {De Ruysscher}, {D. K. M.} and Schols, {A. M. W. J.}",

note = "Funding Information: The authors would like to thank Yves Willems for the retrieval of GTV data, and Karin Sanders for the provision of supportive data. Funding. This research was supported by the NUTRIM Graduate Programme. Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2020 Willemsen, Degens, Baijens, Dingemans, Hoeben, Hoebers, De Ruysscher and Schols.",

year = "2020",

month = nov,

day = "26",

doi = "10.3389/fnut.2020.600612",

language = "English",

volume = "7",

journal = "Frontiers in nutrition",

issn = "2296-861X",

publisher = "Frontiers Media S.A.",

}

Willemsen, ACH, Degens, JHRJ, Baijens, LWJ, Dingemans, A-MC, Hoeben, A , Hoebers, FJP , De Ruysscher, DKM & Schols, AMWJ 2020, 'Early Loss of Fat Mass During Chemoradiotherapy Predicts Overall Survival in Locally Advanced Squamous Cell Carcinoma of the Lung, but Not in Locally Advanced Squamous Cell Carcinoma of the Head and Neck', Frontiers in nutrition, vol. 7, 600612. https://doi.org/10.3389/fnut.2020.600612

Early Loss of Fat Mass During Chemoradiotherapy Predicts Overall Survival in Locally Advanced Squamous Cell Carcinoma of the Lung, but Not in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. / Willemsen, A. C. H.; Degens, J. H. R. J.; Baijens, L. W. J. et al.
In: Frontiers in nutrition, Vol. 7, 600612, 26.11.2020.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Early Loss of Fat Mass During Chemoradiotherapy Predicts Overall Survival in Locally Advanced Squamous Cell Carcinoma of the Lung, but Not in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

AU - Willemsen, A. C. H.

AU - Degens, J. H. R. J.

AU - Baijens, L. W. J.

AU - Dingemans, A-M C.

AU - Hoeben, A.

AU - Hoebers, F. J. P.

AU - De Ruysscher, D. K. M.

AU - Schols, A. M. W. J.

N1 - Funding Information: The authors would like to thank Yves Willems for the retrieval of GTV data, and Karin Sanders for the provision of supportive data. Funding. This research was supported by the NUTRIM Graduate Programme. Publisher Copyright: © Copyright © 2020 Willemsen, Degens, Baijens, Dingemans, Hoeben, Hoebers, De Ruysscher and Schols.

PY - 2020/11/26

Y1 - 2020/11/26

N2 - Background: Cancer cachexia is highly prevalent in advanced non-small cell lung cancer (NSCLC) and locally advanced head and neck squamous cell carcinoma (LAHNSCC), and compromises treatment tolerance and overall survival (OS). NSCLC and LAHNSCC patients share similar risk factors, and receive comparable anti-cancer treatment regimens. The aim of this study was to determine the predictive value of body composition assessed by bioelectrical impedance analysis (BIA) and handgrip strength (HGS) (baseline and early changes during therapy) on OS in NSCLC and LAHNSCC patients treated with platinum-based chemoradiotherapy (CRT) or cetuximab-based bioradiotherapy (BRT). To elucidate potential underlying determinants of early changes in body composition and HGS, specific (fat and fat free) mass loss patterns of squamous NSCLC (sNSCLC) were compared to human papilloma virus negative (HPV-) LAHNSCC patients treated with CRT.Methods: Between 2013 and 2016, BIA and HGS were performed at baseline and after 3 weeks of CRT/BRT in LAHNSCC and NSCLC patients treated with curative intent.Results: Two hundred thirty-three patients were included for baseline measurements. Fat free mass index (FFMI) and HGS2%) in the first 3 weeks of CRT (sNSCLC n = 24, HPV- LAHNSCC n = 23), the FM change was -1.4 +/- 14.5% and -8.7 +/- 9.0% in sNSCLC and HPV- LAHNSCC patients, respectively (p <0.05). Fat fee mass change was -5.6 +/- 6.3% and -4.0 +/- 4.3% for sNSCLC and HPV- LAHNSCC, respectively (p = 0.31).Conclusion: FFMI and HGS

AB - Background: Cancer cachexia is highly prevalent in advanced non-small cell lung cancer (NSCLC) and locally advanced head and neck squamous cell carcinoma (LAHNSCC), and compromises treatment tolerance and overall survival (OS). NSCLC and LAHNSCC patients share similar risk factors, and receive comparable anti-cancer treatment regimens. The aim of this study was to determine the predictive value of body composition assessed by bioelectrical impedance analysis (BIA) and handgrip strength (HGS) (baseline and early changes during therapy) on OS in NSCLC and LAHNSCC patients treated with platinum-based chemoradiotherapy (CRT) or cetuximab-based bioradiotherapy (BRT). To elucidate potential underlying determinants of early changes in body composition and HGS, specific (fat and fat free) mass loss patterns of squamous NSCLC (sNSCLC) were compared to human papilloma virus negative (HPV-) LAHNSCC patients treated with CRT.Methods: Between 2013 and 2016, BIA and HGS were performed at baseline and after 3 weeks of CRT/BRT in LAHNSCC and NSCLC patients treated with curative intent.Results: Two hundred thirty-three patients were included for baseline measurements. Fat free mass index (FFMI) and HGS2%) in the first 3 weeks of CRT (sNSCLC n = 24, HPV- LAHNSCC n = 23), the FM change was -1.4 +/- 14.5% and -8.7 +/- 9.0% in sNSCLC and HPV- LAHNSCC patients, respectively (p <0.05). Fat fee mass change was -5.6 +/- 6.3% and -4.0 +/- 4.3% for sNSCLC and HPV- LAHNSCC, respectively (p = 0.31).Conclusion: FFMI and HGS

KW - hand grip strength (HGS)

KW - locally advanced (stage III) non-small cell lung cancer

KW - locally advanced head and neck cancer

KW - bioelectrical impedance analysis

KW - cachexia

KW - weight loss

KW - chemoradiotherapy (CRT)

KW - OBSTRUCTIVE PULMONARY-DISEASE

KW - CONCURRENT CHEMORADIOTHERAPY

KW - PROGNOSTIC VALUE

KW - CANCER PATIENTS

KW - WEIGHT-LOSS

KW - CHEMOTHERAPY

KW - RADIOTHERAPY

KW - MUSCLE

KW - OUTCOMES

KW - INFLAMMATION

U2 - 10.3389/fnut.2020.600612

DO - 10.3389/fnut.2020.600612

M3 - Article

C2 - 33324671

SN - 2296-861X

VL - 7

JO - Frontiers in nutrition

JF - Frontiers in nutrition

M1 - 600612

ER -